Cardiff Oncology, Inc.
Cardiff Oncology, Inc. (CRDF) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CRDF · as of Jun 8, 2026
Key Statistics
Explore Cardiff Oncology, Inc. Data
crdf stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 14 · Buy rate: 50.0%
The CRDF analyst consensus is Buy, based on ratings from 14 Wall Street analysts over the past 3 months. The average 12-month price target is $2.00, representing +33.33% upside from the current price of $1.50.
Competitors & Peers
crdf competitorsCRDF
APLT
CRBP
ELTX
FBRX
IPHAStock Performance
Full HistoryAbout Cardiff Oncology, Inc.
Cardiff Oncology, Inc. a clinical-stage biotechnology firm located in San Diego, California, is dedicated to developing innovative medical treatments for cancer patients. Its lead therapeutic agent i…
what is cardiff oncology, inc. · crdf stock overview · cardiff oncology, inc. company profile · who is cardiff oncology, inc. ceo · crdf NASDAQ · cardiff oncology, inc. headquarters · cardiff oncology, inc. business segments
About Stock Overview & Key Data
Cardiff Oncology, Inc. (CRDF) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 27, 2004. As of the latest trading session, CRDF stock price is $1.50, with a market capitalization of $102.6M. The stock has returned -61.14% over the past 12 months and -46.62% year-to-date.
According to 14 Wall Street analysts, the consensus rating for Cardiff Oncology, Inc. stock is Buy, with an average 12-month price target of $2.00. In fiscal year 2025, Cardiff Oncology, Inc. reported revenue of $593000.00 and net income of -$45.9M. For detailed data — including Cardiff Oncology, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Cardiff Oncology, Inc. (CRDF) stock price is $1.50. The stock is traded on NASDAQ under the ticker symbol CRDF. The 52-week range is $1.35 – $4.56.